MedDataX Logo

Continuous Lumbar Plexus Block for Postoperative Pain Control After Total Hip Arthroplasty

NCT ID: NCT00790179

Last Updated: 2008-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

225 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-01-31

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Continuous lumbar plexus and femoral blocks have been demonstrated to provide effective postoperative analgesia of the lower extremity following total joint arthroplasty. The purpose of this study was to compare these two techniques when used with intravenous patient-controlled analgesia and the use of patient-controlled analgesia alone for postoperative pain management following unilateral total hip arthroplasty.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

above may be applied

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Continuous lumbar plexus,Femoral,hydromorphone

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PCA;active comparator

Patients with intravenous PCA hydromorphone alone

Group Type ACTIVE_COMPARATOR

continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA

Intervention Type PROCEDURE

0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.

Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.

CFB

Patients with a continuous femoral block (CFB) + PCA hydromorphone

Group Type ACTIVE_COMPARATOR

continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA

Intervention Type PROCEDURE

0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.

Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.

CLPB

Patients with a continuous lumbar plexus block + PCA hydromorphone

Group Type ACTIVE_COMPARATOR

continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA

Intervention Type PROCEDURE

0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.

Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA

0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.

Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-80 years old
* primary diagnosis of osteoarthritis

Exclusion Criteria

* allergy to local anesthetics
* peripheral neuropathy
* opioid dependency
* dementia
* coagulopathy
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Northwell Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Huntington Hospital, North Shore-LIJ Health System

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joseph Marino, M.D.

Role: PRINCIPAL_INVESTIGATOR

Huntington Hospital

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1989md

Identifier Type: -

Identifier Source: org_study_id